Get started
Work

Supplementary Methods S1 from A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas

Year: 2024
Type: supplementary-materials
Abstract: Supplementary Methods S1. Dose-limiting toxicity definitions, Treatment administration, Key inclusion criteria, and Key exclusion criteria.
DOI: 10.1158/1078-0432.27754929
Authors: Olivier Rixe, John L. Villano, Robert Wesolowski, Anne M. Noonan, Vinay K. Puduvalli, Trisha M. Wise-Draper, Richard Curry, Emrullah Yilmaz, Charlie Cruze, Besim Ogretmen, Gilles Tapolsky, Ray Takigiku
Language: English
Open Access status: gold
OpenAlex ID: W4404423591
Cites:
Cited by:
Related to: 10